Subtype
Malignant Female Reproductive System Neoplasm
CI-CAN-00003157Explore in graph →
1,463 active trials11 approved drugs128 evidence items
Loading cancer entity…
Subtype
CI-CAN-00003157Explore in graph →
Clinical trials
6,253 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (740)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06866951 | A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial | withdrawn | Phase 2 / Phase 3 | 0 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT02446652 | Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer | withdrawn | Phase 3 | 0 | National Institute of CancerologíaOTHER_GOV |
| 1 |
| May 29, 2025 |
| clinicaltrials |
| NCT03632798 | Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer(ACSCO) | withdrawn | Phase 3 | 0 | Cordgenics, LLCINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT05712941 | Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer | withdrawn | Phase 3 | 0 | EQRx International, Inc.INDUSTRY | 0 | Nov 3, 2023 | clinicaltrials |
| NCT04943627 | Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA) | withdrawn | Phase 3 | 0 | Agenus Inc.INDUSTRY | 2 | Oct 5, 2022 | clinicaltrials |
| NCT04806945 | A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer | withdrawn | Phase 3 | 0 | Shanghai Henlius BiotechINDUSTRY | 1 | May 5, 2022 | clinicaltrials |
| NCT04795596 | Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers | withdrawn | Phase 2 / Phase 3 | 0 | Menoufia UniversityOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT03905902 | DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma(VITALIA) | withdrawn | Phase 3 | 0 | SOTIO a.s.INDUSTRY | 0 | Dec 23, 2021 | clinicaltrials |
| NCT03806049 | Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer | withdrawn | Phase 3 | 0 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 3 | Jul 15, 2021 | clinicaltrials |
| NCT00693342 | Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission | withdrawn | Phase 3 | 0 | Gynecologic Oncology GroupNETWORK | 0 | Feb 24, 2020 | clinicaltrials |
| NCT03699176 | Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 7) | withdrawn | Phase 3 | 0 | BayerINDUSTRY | 1 | Jan 18, 2020 | clinicaltrials |
| NCT02736435 | Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound | withdrawn | Phase 3 | 0 | Thunder Bay Regional Health Research InstituteOTHER | 1 | Feb 6, 2018 | clinicaltrials |
| NCT01492920 | Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy | withdrawn | Phase 3 | 0 | Gynecologic Oncology GroupNETWORK | 0 | Dec 31, 2014 | clinicaltrials |
| NCT00874302 | Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms | withdrawn | Phase 3 | 0 | Repros Therapeutics Inc.INDUSTRY | 2 | Jun 27, 2014 | clinicaltrials |
| NCT00057928 | S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer | withdrawn | Phase 3 | 0 | SWOG Cancer Research NetworkNETWORK | 2 | Jun 13, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Dec 16, 2025source: clinicaltrials